Where Covetrus Stands With Analysts Within the last quarter, Covetrus (NASDAQ:CVET) has observed the following analyst ratings: Benzinga · Jun 13, 2022
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022 Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period. Benzinga · May 25, 2022
CD&R, TPG Take Covetrus Private In $4B Deal Clayton, Dubilier & Rice (CD&R), a private investment firm, and TPG Capital will acquire animal-health technology and services company Covetrus Inc (NASDAQ:CVET) for $21.00 per share, representing an enterprise value of approximately $4 billion. CD&R and its affiliates currently beneficially own approximately 24% of the company's outstanding shares of common stock. The transaction… Benzinga · May 25, 2022
Raymond James View Skewed Scenarios On Absent Supportive Bid For This Animal Health Stock Raymond James downgraded the rating on Covetrus Inc (NASDAQ:CVET) from Outperform to Market Perform and removed the prior $22 price target after the company received a buyout at $21 per share. Though $21 may not ultimately prove to be the final resting place in terms of the offer price. Raymond James believes the proposed purchase… Benzinga · May 23, 2022
Covetrus: Q4 Earnings Insights Covetrus (NASDAQ:CVET) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Covetrus beat estimated earnings by 4.0%, reporting an EPS of $0.26 versus an estimate of $0.25. Benzinga · Feb 24, 2022
Earnings Preview: Covetrus Covetrus (NASDAQ:CVET) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts estimate that Covetrus will report an earnings per share (EPS) of $0.25. Benzinga · Feb 23, 2022